SCHEMBL378327

SCHEMBL378327

O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(C(=O)N[C@H](c2cccc(F)c2)C2CC2)(c2ccc(F)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
PTPN1 P18031 1/20 0.41
CYP3A4 P08684 5/20 0.41
USP2 O75604 5/20 0.41
CYP2D6 P10635 3/20 0.41
CYP2C9 P11712 3/20 0.41
TSHR P16473 2/20 0.41
CYP1A2 P05177 2/20 0.41
ALDH1A1 P00352 3/20 0.40
OPRL1 P41146 1/20 0.40
MAPK1 P28482 2/20 0.39
HIF1A Q16665 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ABL1 P00519 2/20 0.39
BCR P11274 2/20 0.39
TACR3 P29371 4/20 0.39
SLC6A7 Q99884 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7912322 1.00 HSD11B1 (0.41) HSD11B1PTPN1CYP3A4USP2CYP2D6
SCHEMBL7908348 0.92 HSD11B1 (0.48) HSD11B1PTPN1TSHRALDH1A1OPRL1
SCHEMBL13092454 0.89 GRM5 (0.42) CYP2C9OPRL1TACR3MEN1KMT2A
SCHEMBL13092448 0.88 IDO1 (0.39) CYP2C9CYP1A2TACR3CYP2C19
SCHEMBL13092455 0.87 ALDH1A1 (0.43) CYP3A4CYP2D6CYP2C9TSHRCYP1A2
SCHEMBL13092323 0.86 CYP3A4 (0.47) CYP3A4USP2CYP2D6CYP2C9TSHR
SCHEMBL378796 0.83 AKR1C3 (0.41) USP2CYP2C9TSHROPRL1MAPK1
SCHEMBL7907192 0.78 SLC6A7 (0.47) HSD11B1TSHRMAPK1HPGDSLC6A7
SCHEMBL7908350 0.78 HSD11B1 (0.46) HSD11B1PTPN1OPRL1SLC6A7MEN1
SCHEMBL13092254 0.78 KIT (0.44) HSD11B1PTPN1ALDH1A1SLC6A7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP claimed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 HSD11B1 3638/4885PTPN1 1883/4885CYP3A4 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.